智冉医疗完成3亿元A+轮融资

Core Insights - The core viewpoint of the news is that Zhiran Medical, a leading company in the invasive brain-computer interface (BCI) sector, has successfully completed a 300 million RMB A+ round of financing, indicating strong market recognition of its technological capabilities and growth potential [1][6]. Financing and Market Recognition - Zhiran Medical has completed its second round of financing within six months, attracting significant investment from various stakeholders, including Zhongke Chuangxing and existing investors [1][6]. - The funds raised will primarily be used to advance large-scale clinical trials and iterate high-throughput flexible BCI products, accelerating the technology's clinical application [1][6]. Technological Development - Zhiran Medical has firmly committed to the invasive BCI technology route, leveraging its deep technical expertise and understanding of the industry's future [1][6]. - The company has established a systematic layout in the invasive BCI industry chain, achieving breakthroughs in key technologies such as flexible electrodes, neural chips, decoding algorithms, and electrode implantation robots [3][8]. - A significant technological breakthrough has been made with the development of a stretchable high-throughput flexible electrode, which addresses industry challenges related to traditional linear flexible electrodes [3][8]. Clinical Applications and Future Plans - Zhiran Medical has successfully developed a high-throughput wireless invasive BCI system, enhancing signal stability and decoding accuracy for large-scale clinical applications [4][9]. - The company plans to initiate large-scale registration clinical trials for its over 100-channel invasive BCI products in 2026, following the successful clinical implantation of the first such product in 2025 [4][9]. - The advancements align with national strategic plans and emphasize the importance of independent innovation in cutting-edge technologies [4][9]. Future Outlook - The company aims to accelerate core technology breakthroughs and clinical transformation processes, contributing significantly to China's leadership in the invasive BCI sector [5][10].